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Abstract 
We report a 54-year-old patient with the association of hepatic dysfunction with 
cyanosis, severe hypoxemia, platypnea-orthodeoxia, diffuse cutaneous spider nevi, 
telangiectasia, palmar erythema, digital clubbing and findings of marked intrapulmonary 
vascular dilation and arterovenous shunt. The diagnosis of hepato-pulmonary-cutaneous 
syndrome, a term we think more appropriate and inclusive than that of 
hepato-pulmonary syndrome for this clinicopathological picture, is proposed. The 
putative underlying mechanism for these connected pulmonary and extrapulmonary 
syndromic features is discussed. 
Introduction 
Dyspnea and cyanosis are rare in patients with cirrhosis, except when ascites or pleural 
effusion are present. A diminished arterial partial pressure of oxygen (PaO2) is however 
observed in 50% of decompensated cirrhotic patients, with PaO2 levels in the range of  
60–70 mm Hg [1, 2]. Contributing factors are multifactorial and include: altered 
ventilation-perfusion relationship, especially in patients with ascites and pleural effusions; 
reduced pulmonary diffusing capacity, sometimes due to interstitial edema or dilation of 
precapillary pulmonary vessels; decreased oxygen affinity of red blood cells; pulmonary  
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arterovenous (A-V) anastomosis, either microscopic or involving large vessels; and 
combinations of these factors. Moreover, some patients present the hepato-pulmonary 
syndrome (HPS), characterized by diffuse intrapulmonary vasodilation, A-V shunts or 
both that can lead to abnormal arterial oxygenation, orthopnea, platypnea, and 
orthodeoxia in the setting of liver disease [3]. In fact, patients with the HPS usually have 
chronic liver disease that can be asymptomatic under other aspects, but are often 
admitted to hospital due to chronic respiratory failure and other extrahepatic 
manifestations. Here we describe the case of a woman with HPS, palmar erythema, diffuse 
cutaneous spider nevi, telangiectasia, and digital clubbing, that is a clinical picture we 
could name hepato-pulmonary-cutaneous syndrome (HPCS), and a unifying hypothesis 
for these pulmonary and cutaneous vascular abnormalities is suggested. 
Case Report 
A 54-year-old woman had been well until 15 years before the current observation when elevation of 
serum liver enzymes was noted. Subsequently, she was admitted numerous times in various medical 
departments due to abnormal liver function tests, hypoxia, polyglobulia and dismissed without a 
definite diagnosis. Two years before the current observation, due to increasing grievous exertional 
dyspnea and weight loss (20 kg in the last 2 years), the patient was admitted to another medical ward 
where anti-HCV antibodies enzyme immunoassay, HCV RNA and subsequent liver biopsy confirmed 
the diagnosis of chronic active hepatitis of high severity due to hepatitis C virus infection. The source of 
infection was most probably a blood transfusion 26 years before after postpartum hemorrhage. 
Due to worsening of the exertional dyspnea, even to mild exercise, the patient was admitted to our 
department. Physical examination disclosed superficial polypnea, central cyanosis, digital clubbing, 
palmar erythema, telangiectasia, diffuse spider nevi (fig. 1), and systemic hypotension with a widened 
differential pressure and hepatosplenomegaly. No ascites was detectable on physical examination or by 
ultrasound. Orthodeoxia was observed, since blood gas analysis showed a PaO2 of 38 mm Hg in the 
supine position and of 30 mm Hg in the erect position, only partially corrected with 100% O2. Chest 
radiography and spirometry were negative. Contrast-enhanced echocardiography with saline showed 
evidence of passage of air bubbles from the right ventricle to the left atrium after 4 cardiac cycles, in 
absence of intracardiac right-to-left shunt. Radionuclide imaging with 99mTc-macroaggregated 
albumin showed rapid distribution of radionuclide to the brain and kidney (fig. 2), and a hyperkinetic 
heart syndrome. Thus a diagnosis of HPCS was made with an estimated A-V shunt of 18% while the 
patient was supine and of 40% while the patient was sitting. Additional laboratory evaluation consisted 
of nitric oxide (NO) plasma levels, which were 148 μM (normal 10–60 μM), measured by the Grease 
method, wherase endothelin-1 plasma levels were 58 pg/ml (normal <20 pg/ml) determined by a 
commercially available RIA kit (Amersham). 
Since no widely accepted therapy for HPCS exists, along with the active and untreated liver disease, a 
course of α-interferon was started at a dose of 3,000,000 IU 3 times per week, together with continuous 
low-flow oxygen therapy. 
Discussion 
End-stage liver disease is accompanied by several circulatory abnormalities. 
Cardiopulmonary dysfunction in cirrhosis includes hyperkinetic systemic and splanchnic 
circulation, cirrhotic cardiomyopathy and HPS [1, 2]. HPS generally refers to hypoxemia 
and vascular pulmonary dilation in the setting of liver disease and appears to be relatively 
common, although often subclinical. Severe HPS is rare and has an estimated prevalence 
of 5% in cirrhotic patients. However, the pathogenesis of this syndrome is still unclear. It 
has been postulated that during HPS an impairment of hypoxic vasoconstriction exists, 
which may ultimately lead to marked pulmonary vascular dilation, diffusion-perfusion 
impairment, A-V shunts and ventilation-perfusion mismatch. These gas exchange 
abnormalities may be clinically evident in patients with profound hypoxia, platypnea  
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and/or ortodeoxia, which have already been associated with classic right-to-left shunts. In 
fact, patients with HPS may have venous blood flowing through nonventilated alveoli, or 
bypassing of capillary-alveolar interfaces by venous blood through A-V shunts or 
ineffective oxygenation of deoxygenated hemoglobin molecules due to dilated capillary 
and precapillary beds [3, 4]. Moreover, patients have peripheral A-V vasodilation, 
extrinsicable as spider nevi and pleural vascular abnormalities that resemble cutaneous 
spider nevi, called lung spiders [5, 6]. Systemic vasodilation and hypotension with 
widened differential pressure and elevated cardiac output are often found in HPS patients. 
Although there are not signs, symptoms or hallmarks of HPS on physical examination, 
the presence of cyanosis, severe hypoxemia (partial pressure of oxygen <60 mm Hg) and 
platypnea-orthodeoxia, spider nevi, and digital clubbing strongly suggest HPS [7]. The 
use of contrast-enhanced echocardiography with saline, lung scanning quantification with 
uptake in the brain, or both can distinguish hypoxemia induced by HPS from all other 
causes of hypoxemia [4, 8]. 
The underlying intermediate pathogenetical and biochemical mechanisms are 
probably common to these different pulmonary and extrapulmonary manifestations, so 
we propose the new term of HPCS, which more encompasses the spectrum of coexisting 
clinicopathological abnormalities in this liver-related vascular disorder. Of note, patients 
with cutaneous spider nevi have been reported to have more systemic and pulmonary 
vasodilation, more profound gas exchange abnormalities, and less hypoxic pulmonary 
vasoconstriction, suggesting that spider nevi might be a cutaneous index of 
intrapulmonary vascular dilation [5–7]. Moreover, it seems possible to speculate that 
arterial oxygenation in these patients is dependent on the degree of pulmonary and 
systemic vascular changes. For example, blunted hypoxic pulmonary vasoconstriction is a 
common feature of HPS [3, 4]. We can assume that spider nevi, telangiectasia and 
cutaneous vasodilation when extensively present as in the case of our patient, or the lung 
spiders, can have profound hemodynamical effects that can quite alter PaO2, since the 
shunting of blood from arterial to venous compartments decreases O2 availability to 
tissues, but also decreases oxygen consumption and hypoxemia. Since hypoxia is a potent 
vasoconstrictor, a less marked peripheral arterial deoxygenation can partially influence 
vasodilation and A-V anastomosis, and thus the spider angiomas can modulate vascular 
pulmonary changes. If pulmonary vasodilation and A-V shunts are prevalent, the patient 
will have marked hypoxia, whereas if extrapulmonary vasodilation and A-V 
communications are prevalent, the patient will have a relatively less marked hypoxia in 
pulmonary arterial blood, and this could be involved in the blunted hypoxic pulmonary 
vasoconstriction reported in patients with HPS. Moreover it could help to explain also the 
possible occurrence of both intrapulmonary vascular dilation and anatomical shunt 
without associated hypoxemia that some authors claimed to challenge the definition of 
HPS in some patients [3]. 
The exact biochemical mechanisms behind the production of pulmonary and 
extrapumonary vascular dilation and A-V shunt are not yet known. However, it can be 
supposed that an imbalance between vasoconstrictive and vasodilatory substances that are 
abnormally metabolized by the impaired liver exists. Of note, the criteria for this 
syndrome have been met in patients with any form of liver disease, including acute liver 
failure and ischemic hepatitis [9]. On the contrary, no relationship between the presence 
or severity of HPS and the severity of liver disease as assessed on the basis of 
Child-Turcotte-Pugh classification or the Model for End-Stage Liver Disease has been 
found [10]. Some hypotheses assign a crucial role to NO as a mediator of pulmonary 
vasodilation and impaired arterial oxygenation reported in patient with advanced liver 
disease, and a correlation between the decrease in exhaled NO concentration after liver  
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transplantation and the improvement in oxygenation in these patient has been reported 
[4, 11]. Little is known about the behavior of plasmatic endothelin-1 levels in these 
patients, and there are no data on a possible correlation between the humoral 
modification(s) leading to HPS and cutaneous abnormalities.  
NO of our patient was above physiologic level. Increase in plasma NO may be involved 
in the systemic and pulmonary vasodilation, whereas increased levels of endothelin-1 may 
counteract the effects of NO. High plasma levels of endothelin-1 may also reflect 
decreased availability of endothelin-1 receptors or decreased clearance [12]. In addition, 
since the endothelin-converting enzyme, which transforms pro-endotelin to 
endothelin-1, is situated in the lungs, it is tempting to speculate that the high 
concentration of endothelin-1 in the lungs increases pulmonary vasoconstriction, which 
favors the formation of A-V shunts. Moreover, it has been reported that endothelin-1 
produced during hepatic injury may contribute to HPS by modulating eNOS and 
inducing pulmonary microcirculatory vasodilation [4, 13]. 
Our patient developed digital clubbing, besides pulmonary insufficiency and spider 
nevi. In fact, it is well known that patients with chronic liver disease, chronic 
inflammatory bowel disease, congenital heart diseases with right-to-left shunts, congenital 
anomalous hepatic drainage and type 1b Abernethy malformation can develop digital 
clubbing [4]. Of note, these rare congenital cardiac disorders without liver injury in which 
either hepatic venous blood flow does not reach the lung or portal venous blood reaches 
the inferior vena cava without passing through the liver have clinical similarities to the 
HPS, suggesting that blood from the gut must cross the liver to prevent pulmonary 
vascular dilation [4]. It is thought that digital clubbing develops from the presence in the 
systemic circulation of one or more growth factors that are normally inactivated in the 
lungs [14]. Moreover, one of the known physiologic effects of endothelin-1 is 
mesenchymal cell hyperplasia. In the presence of pulmonary A-V shunts these substances 
find their way to the systemic circulation where they could stimulate digital hyperostosis. 
Even though a number of mechanisms have been proposed to explain pulmonary 
and systemic vascular change in these patients, increased levels of NO and endothelin-1 
seem to be usual findings in this clinical syndrome [4, 15]. In conclusion, we suggest that 
the new term of HPCS is more appropriate and inclusive than that of HPS to summarize 
the diversity, similarity and physiopathological correlations for this unique 
clinicopathological syndrome. 
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Fig. 1. Clinical features of severe HPCS in a 54-year-old woman. Prominent and diffuse spider nevi on 
the thorax. The patient had physical traits of cirrhosis and characteristic signs and symptoms of HPCS 
including severe hypoxemia, platypnea-orthodeoxia, diffuse cutaneous spider nevi, telangiectasia, 
palmar erythema, digital clubbing and findings of intrapulmonary diffusion-perfusion impairment and 
A-V shunt. 
 
 
 
Fig. 2. Radionuclide imaging of the brain, kidneys and lungs (anterior and posterior lungs) showing 
the positive and rapid distribution of the 99mTc-labeled macroaggregated albumin to the kidneys and 
brain. 
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